Xenon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Xenon Pharmaceuticals (XENE) Reports Q1 Loss of $0.42, Revenues Miss
May 11, 2021 4:32 PM EDTXenon Pharmaceuticals (NASDAQ: XENE) reported Q1 EPS of ($0.42), versus ($0.22) reported last year. Revenue for the quarter came in at $4.36 million versus the consensus estimate of $5.15 million.
Dr. Simon Pimstone, Xenons Chief Executive Officer, said, We continue to make excellent progress across both our proprietary and partnered programs. In particular, I... More
